Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.

Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernandez PA, Sees K, Matriano JA, Gaumer K, Daddona PE

The Journal of clinical endocrinology and metabolism26 Oct 2009Cited by 87 (Europe PMC)

PMID19858319PMCIDPMC2805490DOI10.1210/jc.2009-0358PepBankPUB-19858319

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, transdermal teriparatide increased lumbar spine BMD versus placebo in a dose-dependent manner.
In plain wordsIn women with osteoporosis, teriparatide patches increased spine bone density more than placebo patches, with a dose-dependent effect.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Placebo patch
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20, 30, or 40 microg daily · transdermal · 6 monthsAs given in this study (human).
Source sentences
Summary
TPTD delivered by transdermal patch significantly increased lumbar spine BMD vs. placebo patch in a dose-dependent manner at 6 months (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831901
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, procollagen type I N-terminal propeptide increased dose-dependently with active teriparatide treatments and differed significantly from placebo patch.
In plain wordsIn women with osteoporosis, teriparatide increased a bone formation marker compared with baseline and placebo patch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProcollagen type I N-terminal propeptide
Study
n = 165
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Patch 20, 30 or 40 microg daily; injection 20 microg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Bone turnover markers (procollagen type I N-terminal propeptide and C-terminal cross-linked telopeptide of type I collagen) increased from baseline in a dose-dependent manner in all treatment groups and were all significantly different from placebo patch (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831904
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, C-terminal cross-linked telopeptide increased dose-dependently with active teriparatide treatments and differed significantly from placebo patch.
In plain wordsIn women with osteoporosis, teriparatide increased a bone breakdown marker compared with baseline and placebo patch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseC-terminal cross-linked telopeptide of type I collagen
Study
n = 165
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Patch 20, 30 or 40 microg daily; injection 20 microg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Bone turnover markers (procollagen type I N-terminal propeptide and C-terminal cross-linked telopeptide of type I collagen) increased from baseline in a dose-dependent manner in all treatment groups and were all significantly different from placebo patch (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831905
04HumanRandomized controlled trialSafety outcome
In women with osteoporosis, all teriparatide treatments were well tolerated.
In plain wordsIn women with osteoporosis, all teriparatide treatments were well tolerated.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTolerability
Study
n = 165
Outcome group
Adverse events · Whole body
Studied dose
Patch 20, 30 or 40 microg daily; injection 20 microg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
All treatments were well tolerated, and no prolonged hypercalcemia was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831906
05HumanRandomized controlled trialSafety outcome
In women with osteoporosis, no prolonged hypercalcemia occurred with the studied treatments.
In plain wordsIn women with osteoporosis, the study observed no prolonged high blood calcium with the studied treatments.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableProlonged hypercalcemia
Study
n = 165
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Patch 20, 30 or 40 microg daily; injection 20 microg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
All treatments were well tolerated, and no prolonged hypercalcemia was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831907
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, the teriparatide 40-microg patch increased total hip BMD versus placebo patch.
In plain wordsIn women with osteoporosis, the teriparatide patch increased total hip bone density more than the placebo patch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD versus placebo
Study
n: not reported in source
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · transdermal · 6 monthsAs given in this study (human).
Source sentences
Summary
TPTD 40-microg patch increased total hip BMD compared to both placebo patch and TPTD injection (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
Report a problemFND-1985831902

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, the teriparatide 40-microg patch increased total hip BMD more than daily 20-microg teriparatide injection.
In plain wordsIn women with osteoporosis, the 40-microg teriparatide patch increased hip bone density more than daily 20-microg teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD versus injection
Study
n: not reported in source
Comparator
Teriparatide 20 microg daily injection
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
TPTD 40-microg patch increased total hip BMD compared to both placebo patch and TPTD injection (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Our study consisted of 6-month, randomized, placebo-controlled, positive control, multidose daily administration.
Summary · context
A TPTD patch with a 20-, 30-, or 40-microg dose or a placebo patch was self-administered daily for 30-min wear time, or 20 microg of TPTD was injected daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1985831903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00489918

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

Zosano Pharma Corporationn = 165Jun 2007 to Aug 2008

Osteoporosis

Trial page ClinicalTrials.govUpdated 31 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.